Valeant Pharmaceuticals International Inc
Valeant Pharmaceuticals International — Corporate Update (March 2006)
21 slides from Valeant Pharmaceuticals International's corporate update, Mar 21, 2006
Slide 1: Valeant Pharmaceuticals International
_VVALEANT armaceuticals International
Slide 2: Viramidine Safety and Efficacy Versus Ribavirin VISER1 (first of two Phase 3 studies)
VIramidine Safety and Efficacy Versus Ribavirin VISER1 (first of two Phase 3 studies)
Slide 3: VISER1 Summary
VISER1 Summary Confirms superior safety profile Clear dose response based on weight Higher concentrations of Viramidine do not result in proportional increases in anemia Regional anomalies influenced results
Slide 4: Viramidine Phase 3 (VISER1) Study: Design
Viramidine Phase 3 (VISER1) Study: Design Randomized, Double-blind Multicenter, Parallel-group Study in Treatment-naive Subjects (N = 970) 24 weeks of follow-up 24/48 weeks of treatment* Screening (30 days) Randomization (2:1) Follow-up Ribavirin 1000/1200 mg/QD + PegIntron† Viramidine 600 mg BID +
Slide 5: Co-Primary Endpoints
Co-Primary Endpoints Primary safety endpoint: Hemoglobin < 10 g/dL or ^ 2.5 g/dL drop from baseline Superiority test vs. ribavirin Primary efficacy endpoint: Sustained Virologic Response - HCV RNA < 100 copies/mL at FW 24 Non-inferiority test vs. ribavirin
Slide 6: Superiority in Safety Confirmed
Superiority in Safety Confirmed
Slide 7: Safety: Anemia Incidence Hgb <10 g/dL Anytime During Therapy
Safety: Anemia Incidence Hgb <10 g/dL Anytime During Therapy Overall Safety Population Viramidine (FD) Ribavirin (WBD) SVR 0.05 0.23 5% 24% N = 324 N = 646 P<0.0001
Slide 8: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing
Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing
Slide 9: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing
Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing
Slide 10: Per Protocol Population (PP)
Per Protocol Population (PP) Completed protocol specified treatment duration ^ 23 weeks for GT 2,3 ^ 47 weeks for GT non 2,3 Had overall study drug exposure of ^90% for both components of the combination therapy Did not have therapy interruption ^15 days Did not receive any prohibited con-meds (e.g.
Slide 11: Viramidine Efficacy Analysis: Sustained Virologic Response
Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 62% 52% N=646 N=421 N=324 N=216 (-0.002, 0.151) 95% CI for Difference of Proportion (0.072, 0.194) ITT PP
Slide 12: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing
Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing
Slide 13: Sustained Virologic Response Overall by Region (PP)
Sustained Virologic Response Overall by Region (PP) NA EU NA/EU ROW Viramidine (FD) 0.54 0.48 0.51 0.56 Ribavirin (WBD) 0.57 0.54 0.55 0.78 54% 57% 48% 55% 55% 78% 56% 51% 95% CI for Difference of Proportion * Meets non-inferiority criteria N=168 N=100 N=159 N=62 N=327 N=162 N=94 N=54 ? (-0.060, 0.1
Slide 14: Viramidine Efficacy Analysis: Sustained Virologic Response
Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 51% 56% 62% 52% N=646 N=421 N=324 N=216 N=327 N=162 95% CI for Difference of Proportion (-0.060, 0.118) * (-0.002, 0.151) * Meets non-inferiority criteri
Slide 15: Efficacy influenced by: Compliance, Regional anomalies, Weight-based dosing
Efficacy influenced by: Compliance (per protocol) Regional anomalies Weight-based dosing
Slide 16: Viramidine Weight Based Analysis Overall (PP)
Viramidine Weight Based Analysis Overall (PP) Sustained Virologic Response Anemia: <10 g/dL Viramidine mg/kg Viramidine mg/kg <18 19-22 >23 East 0.48 0.64 0.81 47% N=323 66% N=82 81% N=16 <18 19-22 >23 East 0.043 0.024 0.125 2% N=82 4% N=323 12.5% N=16
Slide 17: Sustained Virologic Response Overall Weight Strata NA & EU (PP)
Sustained Virologic Response Overall Weight Strata NA & EU (PP) <=75kg >75kg Viramidine (FD) 0.622 0.419 Ribavirin (WBD) 0.6 0.533 62% 60% 42% 53% 95% CI for Difference of Proportion (-0.034, 0.213) (-0.177, 0.079) * N=148 N=70 N=179 N=92 * Meets non-inferiority criteria
Slide 18: Viramidine Efficacy Analysis: Sustained Virologic Response
Viramidine Efficacy Analysis Sustained Virologic Response Viramidine (FD) 0.38 0.53 0.51 0.62 0.42 Ribavirin (WBD) 0.52 0.62 0.56 0.6 0.53 38% 52% 51% 56% 62% 52% 62% 60% 42% 53% N=646 N=421 N=324 N=148 N=70 N=92 N=179 N=216 N=327 N=162 95% CI for Difference of Proportion (-0.060, 0.118) * (-0.177,
Slide 19: VISER1 Summary
VISER1 Summary Confirms superior safety profile Clear dose response based on weight Higher concentrations of Viramidine do not result in proportional increases in anemia Regional anomalies influenced results
Slide 20: Viramidine Path to Market
Viramidine Path to Market VISER1 Presentation at Scientific Meeting - 1H06 VISER2 Follow-up Completed - End of June 2006 VISER2 Analyses Completed - 2H06 VISER2 Presentation at Scientific Meeting - 4Q06; 1Q07 Market Availability - Before End of 2007
Slide 21: Valeant Pharmaceuticals International
_VVALEANT armaceuticals International
Valeant Pharmaceuticals International — Corporate Update (March 2006) on 6ix